01973nas a2200385   4500000000100000008004100001260001700042653001500059653001000074653000900084653001000093653002400103653003000127653001100157653001100168653001000179653002300189653001200212653000900224653001600233653002000249653002500269653001400294653002400308653000900332653002200341100001100363700001600374245006100390300001100451490000700462050001400469520109000483022001401573       2005                            d  c2005 Jul-Sep10aAdolescent10aAdult10aAged10aChild10aDisease Progression10aDrug Therapy, Combination10aFemale10aHumans10aIndia10aLeprostatic Agents10aleprosy10aMale10aMiddle Aged10aMuscle Weakness10aMycobacterium leprae10aParalysis10aSensation Disorders10aSkin10aTreatment Outcome1 aVara N1 aMarfatiya Y00aA study on the impact of FD-MDT on 200 leprosy patients.  a217-270 v77  aVARA 20053 a<p>A study was carried out from June 1999 to June 2001 to assess the impact of fixed duration multidrug therapy (FD-MDT) in newly detected cases of leprosy in terms of clinical and neurological improvement and changes in the bacillary index of skin smear for AFB. 200 new leprosy cases (both PB & MB) were started on FD-MDT. Of these 200 cases, 16 were of pure neuritic leprosy. After treatment, out of 184 cases with typical skin lesions of leprosy, all 26 PB cases showed inactivity of skin lesions, and, of the remaining 158 MB cases, 40.5% showed inactivity and 59.5% showed complete resolution of skin lesions. Out of 68 skin smear-positive cases, 42 cases with a BI of < or = 3 became smear-negative, while others showed gradual fall in the BI. Such heavily bacilliferous cases were continued with treatment for 1 more year to prevent relapse. As FD-MDT alone does not cure established sensory and motor impairment, it did not show any change in 19% of the patients presented with permanent sensory motor disturbance. FD-MDT prevents progression of sensory/motor disturbance.</p>  a0254-9395